Johnson & Johnson (NYSE:JNJ) Shares Sold by Greenleaf Trust

Greenleaf Trust decreased its position in Johnson & Johnson (NYSE:JNJ) by 10.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 87,954 shares of the company’s stock after selling 10,143 shares during the period. Greenleaf Trust’s holdings in Johnson & Johnson were worth $12,720,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. IFS Advisors LLC raised its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new stake in Johnson & Johnson during the 3rd quarter valued at $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several recent analyst reports. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Raymond James dropped their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company dropped their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $153.54 on Wednesday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $369.66 billion, a price-to-earnings ratio of 23.09, a P/E/G ratio of 2.44 and a beta of 0.52. The stock’s fifty day simple moving average is $147.53 and its 200-day simple moving average is $156.10.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.23%. Johnson & Johnson’s dividend payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.